Reactive oxygen species signalling in the diabetic heart: Emerging prospect for therapeutic targeting

Heart

Volumn 104, Issue 4, 2018, Pages

  Wilson, Adam J ^a   Gill, Eleanor K ^a,b   Abudalo, Rawan A ^a,b   Edgar, Kevin S ^a   Watson, Chris J ^a   Grieve, David J ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b British Society for Cardiovascular Research   (United Kingdom)

Author keywords

Diabetes; heart failure with preserved ejection fraction; myocardial disease basic science; vascular biology

Indexed keywords

HYDROGEN PEROXIDE; MICRORNA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UBIDECARENONE; UNCOUPLING PROTEIN; XANTHINE OXIDASE; CARDIOVASCULAR AGENT;

CARDIAC MUSCLE CELL; CONGESTIVE HEART FAILURE; DIABETIC CARDIAC REMODELLING; DIABETIC CARDIOMYOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; EPIGENETICS; FATTY ACID METABOLISM; GENE THERAPY; GLUCOSE TRANSPORT; HEART FAILURE; HEART MITOCHONDRION; HYPERGLYCEMIA; INSULIN SENSITIVITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; COMPLICATION; DRUG DEVELOPMENT; DRUG EFFECT; HUMAN; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CARDIOVASCULAR AGENTS; DIABETIC CARDIOMYOPATHIES; DISEASE PROGRESSION; DRUG DISCOVERY; HEART FAILURE; HUMANS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 85047762939     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2017-311448     Document Type: Review

References (50)

1. Erqou S, Lee CT, Suffoletto M, et al. Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and metaanalysis. Eur J Heart Fail 2013;15:185-93.
2. Laakso M. Heart in diabetes: a microvascular disease. Diabetes Care 2011;34:S145-S149.
3. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014;57:660-71.
4. Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;2016:2129-200.
5. Zile MR, Jhund PS, Baicu CF, et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circ Heart Fail 2016;9:e002551.
6. Scheen AJ. GLP-1 receptor agonists and heart failure in diabetes. Diabetes Metab 2017;432S(Suppl 1):2S13-2S19.
7. Heusch G, Libby P, Gersh B, et al. Cardiovascular remodelling in coronary artery disease and heart failure. The Lancet 2014;383:1933-43.
8. Li Q, Sun SZ, Wang Y, et al. The roles of MMP-2/TIMP-2 in extracellular matrix remodelling in the hearts of STZ-induced diabetic rats. Acta Cardiol 2007;62:485-91.
9. van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008;117:43-51.
10. Depre C, Young ME, Ying J, et al. Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J Mol Cell Cardiol 2000;32:985-96.
11. Kanamori H, Takemura G, Goto K, et al. Autophagic adaptations in diabetic cardiomyopathy differ between type 1 and type 2 diabetes. Autophagy 2015;11:1146-60.
12. Xie Z, Lau K, Eby B, et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 2011;60:1770-8.
13. Mellor KM, Bell JR, Young MJ, et al. Myocardial autophagy activation and suppressed survival signaling is associated with insulin resistance in fructose-fed mice. J Mol Cell Cardiol 2011;50:1035-43.
14. Finck BN, Lehman JJ, Leone TC, et al. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002;109:121-30.
15. Schilling JD. The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promise. Antioxid Redox Signal 2015;22:1515-26.
16. Kawata T, Daimon M, Miyazaki S, et al. Coronary microvascular function is independently associated with left ventricular filling pressure in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2015;14:98.
17. Cheung N, Wang JJ, Rogers SL, et al. Diabetic retinopathy and risk of heart failure. J Am Coll Cardiol 2008;51:1573-8.
18. Diamant M, Lamb HJ, Smit JWA, et al. Diabetic cardiomyopathy in uncomplicated type 2 diabetes is associated with the metabolic syndrome and systemic inflammation. Diabetologia 2005;48:1669-70.
19. Park CW, Kim HW, Lim JH, et al. Vascular endothelial growth factor inhibition by dRK6 causes endothelial apoptosis, fibrosis, and inflammation in the heart via the Akt/eNOS axis in db/db mice. Diabetes 2009;58:2666-76.
20. Huynh K, Bernardo BC, McMullen JR, et al. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther 2014;142:375-415.
21. Cave AC, Brewer AC, Narayanapanicker A, et al. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 2006;8:691-728.
22. Shen X, Zheng S, Metreveli NS, et al. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006;55:798-805.
23. Block K, Gorin Y, Abboud HE. Subcellular localization of Nox4 and regulation in diabetes. Proc Natl Acad Sci U S A 2009;106:14385-90.
24. Ide T, Tsutsui H, Hayashidani S, et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 2001;88:529-35.
25. Zhang M, Shah AM. ROS signalling between endothelial cells and cardiac cells. Cardiovasc Res 2014;102:249-57.
26. Alp NJ, Mussa S, Khoo J, et al. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J Clin Invest 2003;112:725-35.
27. Ca2+ transients. Circulation 2004;109:1886-91.
28. Battelli MG, Bolognesi A, Polito L. Pathophysiology of circulating xanthine oxidoreductase: New emerging roles for a multi-tasking enzyme. Biochim Biophys Acta 1842;2014:1502-17.
29. Dogan A, Yarlioglues M, Kaya MG, et al. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press 2011;20:182-7.
30. Rajesh M, Mukhopadhyay P, Bátkai S, et al. Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. J Cell Mol Med 2009;13:2330-41.
31. Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation 2015;131:1763-71.
32. Takac I, Schröder K, Zhang L, et al. The E-loop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4. J Biol Chem 2011;286:13304-13.
33. Ray R, Murdoch CE, Wang M, et al. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol 2011;31:1368-76.
34. -/- mice. Cardiovasc Res 2012;94:20-9.
35. Murdoch CE, Chaubey S, Zeng L, et al. Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial-mesenchymal transition. J Am Coll Cardiol 2014;63:2734-41.
36. Sukumar P, Viswambharan H, Imrie H, et al. Nox2 NADPH oxidase has a critical role in insulin resistance-related endothelial cell dysfunction. Diabetes 2013;62:2130-4.
37. Gray SP, Di Marco E, Kennedy K, et al. Reactive oxygen species can provide atheroprotection via NOX4-dependent inhibition of inflammation and vascular remodeling. Arterioscler Thromb Vasc Biol 2016;36:295-307.
38. Zheng D, Dong S, Li T, et al. Exogenous Hydrogen Sulfide Attenuates Cardiac Fibrosis Through Reactive Oxygen Species Signal Pathways in Experimental Diabetes Mellitus Models. Cell Physiol Biochem 2015;36:917-29.
39. Hafstad AD, Nabeebaccus AA, Shah AM. Novel aspects of ROS signalling in heart failure. Basic Res Cardiol 2013;108:359.
40. Lamas GA, Navas-Acien A, Mark DB, et al. Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy. J Am Coll Cardiol 2016;67:2411-8.
41. Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized doubleblind trial. JACC Heart Fail 2014;2:641-9.
42. Ni R, Cao T, Xiong S, et al. Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy. Free Radical Biology and Medicine 2016;90:12-23.
43. Vegter EL, van der Meer P, de Windt LJ, et al. MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail 2016;18:457-68.
44. Nanduri J, Peng Y-J, Wang N, et al. Epigenetic regulation of redox state mediates persistent cardiorespiratory abnormalities after long-term intermittent hypoxia. J Physiol 2017;595:63-77.
45. Kietzmann T, Petry A, Shvetsova A, et al. The epigenetic landscape related to reactive oxygen species formation in the cardiovascular system. Br J Pharmacol 2017;174:1533-54.
46. Bernardo BC, Gao X-M, Winbanks CE, et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proceedings of the National Academy of Sciences 2012;109:17615-20.
47. Kornicka K, Marycz K, Marȩdziak M, et al. The effects of the DNA methyltranfserases inhibitor 5-Azacitidine on ageing, oxidative stress and DNA methylation of adipose derived stem cells. J Cell Mol Med 2017;21:387-401.
48. Bish LT, Morine K, Sleeper MM, et al. Adeno-Associated Virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther 2008;19:1359-68.
49. Kawase Y, Ly HQ, Prunier F, et al. Reversal of Cardiac Dysfunction After Long-Term Expression of SERCA2a by Gene Transfer in a Pre-Clinical Model of Heart Failure. J Am Coll Cardiol 2008;51:1112-9.
50. Greenberg B, Butler J, Felker GM, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. The Lancet 2016;387:1178-86.